The sole question on appeal was whether it would have been obvious to make zolmitriptan into a nasal spray. The Federal Circuit agreed with the district court that the prior art taught away from formulating zolmitriptan for intranasal administration.
The post Nasal Spray Patents Covering Migraine Drug Zomig Not Invalid As Obvious appeared first on IPWatchdog.com | Patents & Patent Law.
Patent
- Enablement
- Fee Shifting
- Litigation
- Other Barks & Bites for Friday, July 23: FTC to Enforce Antitrust Laws Against Repair Restrictions, USPTO Updates Arthrex Guidance, and FAIR Contributions Act Introduced to Study Big Tech USF Contributions
- Patent Filings Roundup: Equitable IP Subsidiary Goes on Retail Shopping Spree; Fintiv ITC Denial Hits Roku Hard
- Drilling Down on Criticism of Top-Down Approach to Determining Essentiality
- The Biden Executive Order’s Restraint on Freedom of Contract: Regulation by Anecdote May Lead to Unintended Consequences
- IP Goes Pop! Ep #2: Intellectual Property Urban Legends – Taking on Myths About IP in Popular Culture
Recent Posts
- Other Barks & Bites for Friday, July 23: FTC to Enforce Antitrust Laws Against Repair Restrictions, USPTO Updates Arthrex Guidance, and FAIR Contributions Act Introduced to Study Big Tech USF Contributions
- Patent Filings Roundup: Equitable IP Subsidiary Goes on Retail Shopping Spree; Fintiv ITC Denial Hits Roku Hard
- Drilling Down on Criticism of Top-Down Approach to Determining Essentiality
- The Biden Executive Order’s Restraint on Freedom of Contract: Regulation by Anecdote May Lead to Unintended Consequences
- IP Goes Pop! Ep #2: Intellectual Property Urban Legends – Taking on Myths About IP in Popular Culture